Shire taps Rani Therapeutics ’ oral delivery tech for hemophilia therapy

Shire (NSDQ:SHPG) said this week that it is collaborating with Rani Therapeutics to combine the company’s Rani Pill technology for the delivery of factor VIII therapy in patients with hemophilia A. According to the terms of the deal, Shire has the exclusive option to negotiate a license to develop and commercialize the technology as a delivery mechanism for FVIII therapy after the companies conduct feasibility studies. Shire also made an equity investment into Rani Therapeutics as part of the collaboration. Get the full story at our sister site, Drug Delivery Business News. The post Shire taps Rani Therapeutics’ oral delivery tech for hemophilia therapy appeared first on MassDevice.
Source: Mass Device - Category: Medical Devices Authors: Tags: Biotech Drug-Device Combinations Pharmaceuticals Research & Development Wall Street Beat ranitherapeutics Shire Plc. Source Type: news